M-A: Tirzepatide cardiovascular event risk assessment.
18 May, 2022 | 10:34h | UTCTirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Commentary: Meta-analysis backs tirzepatide CV safety – medwireNews
Commentary on Twitter
https://twitter.com/NatureMedicine/status/1497179669476614150